ECM
NKTR icon

ExodusPoint Capital Management’s Nektar Therapeutics NKTR Stock Holding History

ExodusPoint Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.47M Buy
+20,457
New +$1.16M 0.01% 883
2024
Q4 		– Sell
-18,691
Closed -$364K – 1877
2024
Q3 		$364K Buy
+18,691
New +$356K ﹤0.01% 1296
2023
Q1 		– Sell
-32,833
Closed -$1.11M – 2011
2022
Q4 		$1.11M Buy
32,833
+30,763
+1,486% +$1.49M 0.02% 894
2022
Q3 		$99K Buy
+2,070
New +$123K ﹤0.01% 1746
2022
Q2 		– Sell
-27,714
Closed -$2.24M – 2272
2022
Q1 		$2.24M Buy
27,714
+26,322
+1,891% +$3.9M 0.03% 721
2021
Q4 		$282K Sell
1,392
-2,392
-63% -$519K ﹤0.01% 1686
2021
Q3 		$1.02M Buy
3,784
+920
+32% +$221K 0.01% 1017
2021
Q2 		$737K Buy
+2,864
New +$793K 0.01% 1160
2021
Q1 		– Sell
-1,103
Closed -$281K – 2440
2020
Q4 		$281K Sell
1,103
-2,264
-67% -$585K ﹤0.01% 1576
2020
Q3 		$838K Buy
3,367
+996
+42% +$313K 0.02% 762
2020
Q2 		$824K Buy
+2,371
New +$740K 0.02% 839
2020
Q1 		– Sell
-2,752
Closed -$891K – 1462
2019
Q4 		$891K Buy
+2,752
New +$798K 0.02% 602

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ExodusPoint Capital Management's NKTR Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 20,457 shares worth $1.47M. The stake represents 0.01% of the portfolio and ranks #883 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in NKTR as recently as Q3 2024.

ExodusPoint Capital Management first reported a position in NKTR in Q4 2019 and has held it in 12 quarters since. The position peaked at $2.24M in Q1 2022. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • ExodusPoint Capital Management held 20,457 shares of Nektar Therapeutics worth $1.47M as of Q1 2026.
  • Nektar Therapeutics was a new ExodusPoint Capital Management position in Q1 2026.
  • Nektar Therapeutics made up 0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #883 holding.
  • ExodusPoint Capital Management first reported a position in Nektar Therapeutics in Q4 2019 and has held it in 12 quarters since.
  • ExodusPoint Capital Management's Nektar Therapeutics position peaked at $2.24M in Q1 2022.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.